- Home
- SES vs BIOA Comparison
SES vs BIOA Comparison
Compare SES & BIOA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SES | BIOA |
|---|---|---|
| Founded | 2012 | 2015 |
| Country | United States | United States |
| Employees | N/A | 64 |
| Industry | Auto Parts:O.E.M. | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 719.2M | 856.3M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | SES | BIOA |
|---|---|---|
| Price | $1.13 | $19.44 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 5 |
| Target Price | $4.00 | ★ $51.80 |
| AVG Volume (30 Days) | ★ 8.8M | 458.7K |
| Earning Date | 03-04-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $148.49 | N/A |
| Revenue Next Year | $170.97 | $898.47 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.42 | $2.88 |
| 52 Week High | $3.73 | $24.00 |
Technical Indicators
Market Signals| Indicator | SES | BIOA |
|---|---|---|
| Relative Strength Index (RSI) | 33.90 | 46.48 |
| Support Level | $1.02 | $18.62 |
| Resistance Level | $1.22 | $22.25 |
| Average True Range (ATR) | 0.11 | 1.49 |
| MACD | -0.01 | -0.19 |
| Stochastic Oscillator | 9.85 | 26.06 |
Price Performance
Historical ComparisonAbout SES SES AI Corporation
SES AI Corp is a developer and manufacturer of high-performance, AI-enhanced Lithium-Metal (Li-Metal) and Lithium-ion (Li-ion) rechargeable battery technologies for electric vehicles (EVs), Urban Air Mobility (UAM), drones, robotics, Battery Energy Storage Systems (BESS) and other applications. It includes Software and Hardware products that are EV, UAM, Drone, Molecular Universe, and Avatar.
About BIOA BioAge Labs Inc.
Bioage Labs Inc is a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases, such as obesity, by targeting the biology of human aging. Its focus is metabolic disease, one of the greatest healthcare challenges. The pipeline Products of the company are NLRP3 inhibitors, APJ against, and others.